Joseph Mercola
Semaglutide, the blockbuster drug being used for weight loss, is slated to bring in more than $10 billion in annual sales but serious adverse e!ects are emerging.
A study using data from Eudravigilance, Europe’s system for analyzing adverse reactions to medications, found a high prevalence of gastrointestinal disorders among users.
Other semaglutide patients “experienced rapid worsening of kidney function” after use.
Semaglutide has also been associated with cancer, pancreatitis and retinopathy complications, including hemorrhage and blindness.
Long-term use of GLP-1RAs like semaglutide may even leave your small intestine as inelastic as a loose spring, causing a potentially fatal intestinal obstruction.
Image: Towfiqu barbhuiya @ Unsplash
